SI
SI
discoversearch

 Biotech / Medical | Beat the Market Biotechs


Previous 10 | Next 10 
From: Western Rookie4/12/2012 10:02:44 PM
   of 72
 
Fatty acids fight cancer spread

Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary stage cancers according to pharmacy researchers at the University of Sydney.

Investigators in the Faculty of Pharmacy’s Pharmacogenomics and Drug Development Group are using breast cancer tissue cells to gauge the blocking capacity of the omega-3 agents called epoxides on cancer cell movement.

Dr Michael Murray, Professor of Pharmogenetics at the University, says a major life-threatening consequence of malignant breast tumours is metastasis where the disease has spread to distant sites (or tissues) and at present there are no treatments.

He led his team to the discovery of the anti-metastatic actions of epoxides which are produced within the body from omega-3 polyunsaturated fatty acids. The ground-breaking work has led Murray and his Drug Development Group deeper into the molecular structure of the omega-3 agents.

Professor Murray says:

“These agents are a bit like frontline soldiers blocking the assault of an invading army and now we want to advance our research which was published late last year and apply it to breast cancer cells.”

“We know that epidemiological studies have reported that dietary intake of omega-3 polyunsaturated fatty acids including eicosapentaenoic and docosahexaenoic acids, decrease the risk of certain cancers. And many of us are including sources of omega-3 such as tuna and salmon in our diet as a precaution.”

“The major objective of our new project is to speed the development of anti-metastatic agents based on Omega-3 epoxides and trial their effectiveness in vivo on breast cancer tissue.”

“Longer term we are aiming to develop a completely new class of anti-metastatic drugs designed to inhibit the spread of primary cancers,” Murray says.

Although not all experts agree, women who eat foods rich in omega-3 fatty acids over many years may be less likely to develop breast cancer. More research is needed to understand the effect that omega-3 fatty acids may have on the prevention of breast cancer says Murray.

Research has also shown that omega-3 fatty acids reduce inflammation and may help lower risk of chronic diseases such as heart disease and arthritis.

Source: www.sydney.edu.au

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie4/18/2012 2:00:38 PM
   of 72
 
Chemaphor Releases Business Overview Video


from Thenewswire.ca - RSS (all) by news@thenewswire.ca (TheNewswire.ca)





OTTAWA, ONTARIO, April 18, 2012 - Chemaphor has released a video summary presentation of its multi-product business development platform based on its novel OxC-beta technology. The presentation, which may be viewed at the Chemaphor website (www.chemaphor.com), is made by CEO David Hankinson who describes how the unusual combination of immune properties of OxC-beta can benefit companion animals, food-production animals and humans globally.

About OxC-beta

OxC-beta is Chemaphor's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

Forward Looking Statements This news release and the video referred to above include certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained in this release or in the video referenced above that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described in the video referred to above are based on historical results. Different animals may experience different results from the treatments described above.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie4/19/2012 10:40:01 AM
   of 72
 
Chemaphor Receives First U.S. Order For Oximunol (tm) Chewables


OTTAWA, ONTARIO, April 19, 2012 - Avivagen Animal Health Inc., the commercial arm of Chemaphor Inc. (TSXV:CFR), is pleased to announce that it has received the first order for Oximunol(TM) Chewables for dogs for the veterinary market in the U.S. This follows on from the recent announcement of its distribution agreement for Oximunol(TM) Chewable Tablets in the U.S. and accreditation from the National Animal Supplement Council of Oximunol(TM) companion animal supplement products in the U.S. David Hankinson, CEO of Chemaphor, said "This achievement of an order for product is a major milestone in Chemaphor's strategy to expand into the International market with products that can improve the quality of life for companion animals. We are pleased by the size of this first purchase order and are excited that Oximunol(TM) Chewable Tablets, which has been so well-received by dog owners in the Canadian market, finally will become available to dog owners in the US through their veterinarians." Dave Hankinson also added, "This is a great first step in our international commercial efforts and brings our investors validation of demand for our Oximunol(TM) Chewables, while we seek distribution agreements in other territories and also aim to bring follow-on products to market."

About Oximunol(TM) Chewables - Optimized health in a chewable tablet

Oximunol(TM) is a scientifically formulated chewable tablet that contains Chemaphor's proprietary, patented active ingredient OxC-beta. OxC-beta is a highly concentrated version of oxidized derivatives of carotenoids that are found naturally and extensively in the plant world in minute amounts. It is currently available for dogs of all ages. Oximunol(TM) Chewables work with a dog's own immune system to optimize overall health and well-being, including:

+Promotes and supports healthy joint function

+Promotes and maintains normal mobility

+Enhances healthy condition of skin and coat

+May help discomfort associated with normal daily activity

+Leads to maintenance of normal intestinal function

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

About Avivagen

Avivagen, a wholly-owned subsidiary of Chemaphor, is dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Share Recommend | Keep | Reply | Mark as Last Read


From: Western Rookie4/19/2012 10:41:08 AM
   of 72
 
Theralase Reports Expanded Cancer Drug Technology




Toronto, Ontario -- April 19, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that it has been issued a new U.S. Patent that expands the scope and capabilities of its cancer-fighting proprietary Photo Dynamic Compound (PDC) technology. The patent provides Theralase with exclusive rights to a new and advanced class of anti-cancer and anti-bacterial compounds until 2031.

Theralase continues to expand its intellectual property holdings of cancer-fighting drug compounds employed in conjunction with its proprietary therapeutic laser device capabilities. The newly issued U.S. Patent expands the Company's capability to jointly employ its proprietary PDC and laser technologies in the destruction of a diverse variety of common cancers, bacteria and viruses. The new PDC patent identifies a special class of proprietary Photo Dynamic Compounds that can be employed in the destruction of bulk tumours.

Theralase recently reported that the growth of subcutaneous (under the skin) colon cancer tumours in mouse subjects, which were simultaneously treated with the Theralase anti-cancer PDC technologies have continued to thrive cancer-free for more than 55 days post-treatment and without any side effects.

Based on the Company's recent successes in the research and development of its portfolio of patented PDCs, there is increased confidence that applications can be made to the regulatory bodies for human trials in the relatively near future.

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technology.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & Chief Executive Officer

416-447-8455 ext. 225

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com

Arkady Mandel

Chief Scientific Officer

416-447-8455 ext. 242

amandel@theralase.com

Greg Bewsh

Director of Investor Relations

416-447-8455 ext. 262

gbewsh@theralase.com

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie5/8/2012 12:35:34 PM
   of 72
 
biOasis Transcend Vector Delivers an Anti-Amyloid Beta (AB) Antibody To The Brain

biOasis Technologies Inc.

TSX VENTURE : BTI




May 08, 2012 09:00 ET


- UPDATE -

Four (4) Fold Increase In Brain Penetration



VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 8, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) today announces test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain. The results demonstrate that Transcend can increase considerably the delivery of an anti-amyloid beta antibody (anti-Aß) to the brain. Further to the work performed at the National Research Council of Canada (NRC) and announced by the company on November 1st, 2011, the brains of the subject animals were sent to the iCapture Centre (St Paul's Hospital, Vancouver, BC) for quantitative analysis by confocal microscopy. The analysis showed that Transcend successfully delivered greater than 4 fold more anti-Aß into the brain when compared to anti-Aß on its own. One of the challenges facing companies currently testing anti-Aß antibodies in clinical trials for the treatment of Alzheimer's disease (AD) is getting enough of the antibody to cross the blood-brain barrier and into the brain. The passive immunization of AD patients using antibodies directed at the Aß peptide is a potential therapeutic strategy aimed at reducing amyloid plaques in the brain. The plaques, consisting of insoluble amyloid ß protein are thought to be responsible for the neuronal cell death and the associated cognitive impairment seen in AD patients. Approaches that can efficiently deliver these antibodies into the brain may be the key for their use in the treatment of AD.

"As we reported earlier, a number of pharmaceutical companies are in early and late stage clinical trials studying anti-Aß antibodies as potential treatments for AD. biOasis has shown over the past several months that its Transcend Vector can deliver antibodies such as anti-Aß (reported here), Herceptin®1, and other large and small molecules across the blood-brain barrier to achieve higher concentrations than those seen with the effector molecules on their own," said Rob Hutchison, CEO. "Through the use of confocal microscopic imaging, we have been able to quantify the increase in brain penetration using Transcend. In the case of the anti-Aß antibody, we showed two observations at a 2 hour time point; 1) the amount of the injected dose that reached the brain capillary network was 6 times that of the anti-Aß antibody on its own and 2) the amount of Transcend-anti-Aß antibody conjugate that crossed the Blood-Brain Barrier and entered the brain tissue was greater than four (4) fold over that seen with the anti-Aß antibody on its own. If indeed anti-Aß antibodies can provide a treatment for Alzheimer's Disease, our Transcend Vector may play a key role in facilitating the delivery of these antibodies and potentially contribute to the development of new therapeutic approaches to treating AD."

ABOUT TRANSCEND

biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood-brain barrier - Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood-brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and genes that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts. It is widely reported that over 95% of all Therapeutic molecules do not cross the blood-brain barrier. To address the unmet clinical need to transport drugs across the blood brain barrier biOasis intends to license Transcend to multiple corporate partners.

1. Herceptin® is a registered trademark of Genentech

ABOUT BIOASIS:

biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications. biOasis is also developing Cognitest, a blood test to potentially aid clinicians in the diagnosis of Alzheimer's disease.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie5/8/2012 12:37:40 PM
   of 72
 
Abattis Announces National Distribution Agreement with Hedley Enterprises Ltd.

Abattis Biologix Corporation

CNSX : FLU




May 03, 2012 08:00 ET


Highlights

-- 5 year Agreement

-- Hedley will distribute and market Abattis' products across Canada

-- Hedley has an established distribution channel of 2,400 retail outlets

-- Agreement will result in Abattis' first source of revenue



VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 3, 2012) - Abattis Biologix Corporation (the "Company" or "Abattis") (CNSX:FLU), has entered into an exclusive distribution agreement (the "Agreement") with Hedley Enterprises Ltd. ("Hedley") to purchase, resell and distribute Abattis' line of natural products in Canada. Under the terms of the Agreement Hedley has acquired the exclusive right to sell and distribute Abattis' products to all retail distribution channels including: health food stores, grocery stores, fitness facilities, and similar retail establishments. Hedley has existing sales channels into 2,400 retail outlets across Canada.

"We are excited to be working with Hedley Enterprises and to have them introduce and market our products to the Canadian market. This agreement will result in our first source of revenue," said Mike Withrow, President and CEO of Abattis.

About Hedley Enterprises Ltd.

Hedley specializes in distributing unique and proprietary natural health products. Hedley Enterprises Ltd. was founded July 1, 1977 by Bob Hedley. Throughout this time, Bob has come to realize that superior service must be the number one priority in order to provide a quality product in a place of business where people feel welcome and cared for. As a result, re-sellers enjoy this superior service throughout the company.

About Abattis Biologix Corporation

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The Company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

Mike Withrow, Director


Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Share Recommend | Keep | Reply | Mark as Last Read


From: Western Rookie5/16/2012 11:10:02 AM
   of 72
 
Breaking News on Supplements & Nutrition - North America Beta-glucan ingredient may boost immune function for athletes: Study By Stephen Daniells, 11-May-2012 Related topics: Immune system, Research

Daily supplements of the beta-glucan based ingredient Wellmune WGP may alter immune function after strenuous exercise, says a new study from the University of Houston.

Strenuous exercise is known to weaken or suppress the immune function, making some athletes more prone to infection and illness. New data published in the British Journal of Nutrition suggests that ten days of supplementation with Wellmune WGP may increase levels of total and pro-inflammatory white blood cells (monocytes) after exercise.

“These findings support the notion that supplementation with the Wellmune WGP form of baker’s yeast beta-glucan before exercise altered the typical post-exercise innate immune response,”wrote the researchers, led by Dr Brian McFarlin.

“More research is needed to understand what the clinical implications of the observed changes are.”

The ingredient

Wellmune WGP, derived from the cell walls of a proprietary strain of yeast (Saccharomyces cerevisiae) via a patented manufacturing process, is a natural carbohydrate that activates key immune cells.

Designed for use with foods, beverages and premium supplements, Wellmune can be used in a large number of subcategories in each segment. For example, beverages example, may include dairy, waters, teas, juices, sports drinks and other functional beverages, as well as powdered beverages.

Study details

Dr McFarlin and his co-workers evaluated the effects of 10 days of supplementation with Wellmune WGP on post-exercise immunosuppression. They recruited 60 active men and women and assigned them to receive either the beta-glucan ingredient or placebo (rice flour) for 10 days. The participants then crossed over to the other intervention after a seven-day washout period in between.

The participants were asked to complete bouts of strenuous exercise by cycling for about 50 minutes in hot and humid conditions.

Results showed that total and pro-inflammatory monocyte levels were “significantly greater” two hours after exercise following the Wellmune phase, compared with the placebo phase.

“The key findings of the present study demonstrate that beta-glucan may have potential to alter immunity following a strenuous exercise session,”wrote the researchers.

Source: British Journal of Nutrition
Published online ahead of print, doi: 10.1017/S0007114512001407
“Baker's yeast ß-glucan supplementation increases monocytes and cytokines post-exercise: implications for infection risk?”
Authors: K. C. Carpenter, W. L. Breslin, T. Davidson, A. Adams and B. K. McFarlin

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie5/16/2012 5:40:38 PM
   of 72
 
Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology


Stellar Executes Agreement With University of Guelph for Vaccine Research
PORT HUENEME, CA--(Marketwire - April 10, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) today announced that it has entered into an agreement with the University of Guelph (Ontario, Canada) for the exclusive option to license technology for the development of a vaccine candidate against Clostridium difficile infection ("CDI").

Clostridium difficile is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. CDI causes severe diarrhea and life-threatening intestinal conditions such as colitis. CDI is a major and growing cause of mortality and morbidity in hospitalized patients. In the United States, incidence of CDI is at a record high with 336,600 cases reported in 2009 and projected to continue to increase.

"The use of non-antibiotic-based approaches to control Clostridium difficile colonization may offer an important treatment option for CDI," said Herbert Chow, Ph.D., Stellar Vice President of Product Development. "Stellar is committed to identifying promising vaccine candidates such as for CDI or other disease targets that may be synergistic with our KLH platform."

Professor Mario A. Monteiro (University of Guelph) commented that, "It is very gratifying to our research group that Stellar is taking the lead in commercializing our C. difficile vaccine technology, and to see that our scientific discoveries may soon be available to the public and provide a significant positive impact on global health."

The cost of CDI-related treatments in the U.S. and European countries is estimated at more than $7 billion a year. The recent emergence and spread of hyper-virulent strains of Clostridium difficile further underscore the importance of developing novel approaches to preventing and treating CDI.

For more about CDI, visit:

Public Health Agency of Canada phac-aspc.gc.ca 

Centers for Disease Control and Prevention cdc.gov 

About the University of Guelph

The University of Guelph is ranked as one of Canada's top comprehensive universities because of its commitment to student learning and innovative research. University of Guelph is dedicated to cultivating the essentials for quality of life -- water, food, environment, animal and human health, community, commerce, culture and learning. It also shares a profound sense of social responsibility, an obligation to address global issues and a concern for international development.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of stellarbiotechnologies.com 

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie6/18/2012 12:55:16 PM
   of 72
 
Well... I got the call in Biotechs right earlier this year with Biotechs being the hottest sector of any!

BTI-V is strong. Neptune and Acasti holding. But when is the money going to trickle down to these spec stocks?

Seriously... Abattis has some of the coolest products out there. If this company gets the money to produce they will sell.

I am a DefenZall convert. I take the product everyday and it has really helped me out. Last year I not only had a problem with me knee and being able to run consistently. The most I could do was 2 runs (11km + 7km) a week for 3 weeks and then my knee was toast. On top of that I had immune function problems which kept me from intense workout activity without me getting sick or at least suffering extreme fatigue. 2 hour bike rides were out the window.

I a sure 1 extra year of healing in my knee has something to do with it as well but this was the same even in November doing cross country running. I had to quit after prolonged exposure.

I have now been taking DefenZall since February twice a day and have since put together my longest running stretch since my broken leg as well as increased my pace since start by up to 20%. (11km runs were hour plus and now are 50 minutes. ) 7km runs were 36 minutes and are now 30 minutes.

After 2 months of running I did a stretch of 7 runs in 15 days ending with the fastest run I had done since a broken leg. I had to stop running recently because of an over use injury (stress fracture). The dramatic increase in recovery over the last 6 months can largely be attributed to DefenZall. On top of that I have had no immune function problems associated with recovery which plagued me last year.


Last year I was contemplating meds because of declining health and my inability to continue with my lifestyle. In most countries my stats would not allow me to go on meds because my immune system is top notch inspite an ever increasing viral load. I am well above the UN standard for medication. So obviously what I do naturally to stimulate my immune system works very well, but I did not have anything that is a natural anti-viral and this has been evident with an gradually increasing viral load over the last 2 years.

Since I have taken Abattis Biocell algae... (DefenZall). It has undeniably done major benefits to improve my health.

Seriously... Astaxanthin, Ntiric Oxide, krill oils etc... this company will be at the top of the food chain when it comes to leading and cutting edge nutritional supplements.

Basically what is in DefenZall is a bunch of supernutrients and if you look at the report I posted previously you will see the link to nutritional deficiency and people dying of Aids. If I lived in Africa with the treatment I have received (none). I would be dead by now.

A major difference is my access to healthy food and i argue is much more important than drugs. And since I have improved my diet with DefenZall... I have noticed a marked improvement in my own health.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: Western Rookie who wrote (63)6/20/2012 4:55:42 PM
From: The Jack of Hearts
   of 72
 
I am still watching your threads.. but the TSX volume is the most pathetic I have seen... Lots of folks sitting on their hands...

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.